---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-024744"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2022-09-12T23:59:59+00:00"
generated_at: "2026-06-23T10:46:44.618488+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology plans randomized Phase 2 mCRC trial (ONSEMBLE) with topline data in 2H 2024; cash runway into 2025

## Summary
- Phase 1b/2 mCRC data show ORR 35%, mPFS 9.3 mo, median DoR 11.7 mo; historical controls ORR 5-13%, mPFS 4.5-5.7 mo.
- ONSEMBLE trial to enroll ~150 patients randomized 1:1:1 to SoC ± 20/30 mg onvansertib; primary endpoint ORR.
- Phase 2 PDAC trial: 1 PR, 3 SD in 5 evaluable patients; additional data expected Q2/Q3 2023.
- Company stops independent funding of prostate cancer program; will focus on mCRC and PDAC.
- Cash resources expected to fund operations into 2025; investigator-initiated trials in TNBC and SCLC ongoing.

## SEC filing metadata
- accession: 0001628280-22-024744
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2022-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828022024744/0001628280-22-024744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828022024744/crdf-20220910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-024744
- JSON: https://secwatch.observer/filing/0001628280-22-024744.json
- Plain text: https://secwatch.observer/filing/0001628280-22-024744.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.